Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Harding

Showing results (251-260 of 268) with videos related to

Pageof 27
Sort By:
Cancer Discovery|November 15, 2018
<i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian CarcinomaKevin K Lin, Maria I Harrell, Amit M Oza, et al.
Cancer Discovery|September 26, 2013
Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLCAnnette O Walter, Robert Tjin Tham Sjin, Henry J Haringsma, et al.
Scientific Data|April 15, 2025
Materials Data Science Ontology(MDS-Onto): Unifying Domain Knowledge in Materials and Applied Data ScienceBalashanmuga Priyan Rajamohan, Alexander C Harding Bradley, Van D Tran, et al.
Nature Communications|September 30, 2018
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinomaOlga Kondrashova, Monique Topp, Ksenija Nesic, et al.
Nature Communications|April 21, 2018
How high energy fluxes may affect Rayleigh-Taylor instability growth in young supernova remnantsC C Kuranz, H-S Park, C M Huntington, et al.
Nature Communications|August 18, 2021
Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concernDonal T Skelly, Adam C Harding, Javier Gilbert-Jaramillo, et al.
The Lancet. Oncology|December 3, 2016
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trialElizabeth M Swisher, Kevin K Lin, Amit M Oza, et al.
Medrxiv : the Preprint Server for Health Sciences|March 30, 2023
<i>BRCA1</i> secondary splice-site mutations drive exon-skipping and PARP inhibitor resistanceKsenija Nesic, John J Krais, Cassandra J Vandenberg, et al.
Lancet (London, England)|September 17, 2017
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trialRobert L Coleman, Amit M Oza, Domenica Lorusso, et al.
Molecular Cancer|August 5, 2024
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistanceKsenija Nesic, John J Krais, Yifan Wang, et al.
Pageof 27

Showing results (251-260 of 268) with videos related to

Sort By:
Pageof 27
Cancer Discovery|November 15, 2018
<i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian CarcinomaKevin K Lin, Maria I Harrell, Amit M Oza, et al.
Cancer Discovery|September 26, 2013
Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLCAnnette O Walter, Robert Tjin Tham Sjin, Henry J Haringsma, et al.
Scientific Data|April 15, 2025
Materials Data Science Ontology(MDS-Onto): Unifying Domain Knowledge in Materials and Applied Data ScienceBalashanmuga Priyan Rajamohan, Alexander C Harding Bradley, Van D Tran, et al.
Nature Communications|September 30, 2018
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinomaOlga Kondrashova, Monique Topp, Ksenija Nesic, et al.
Nature Communications|April 21, 2018
How high energy fluxes may affect Rayleigh-Taylor instability growth in young supernova remnantsC C Kuranz, H-S Park, C M Huntington, et al.
Nature Communications|August 18, 2021
Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concernDonal T Skelly, Adam C Harding, Javier Gilbert-Jaramillo, et al.
The Lancet. Oncology|December 3, 2016
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trialElizabeth M Swisher, Kevin K Lin, Amit M Oza, et al.
Medrxiv : the Preprint Server for Health Sciences|March 30, 2023
<i>BRCA1</i> secondary splice-site mutations drive exon-skipping and PARP inhibitor resistanceKsenija Nesic, John J Krais, Cassandra J Vandenberg, et al.
Lancet (London, England)|September 17, 2017
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trialRobert L Coleman, Amit M Oza, Domenica Lorusso, et al.
Molecular Cancer|August 5, 2024
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistanceKsenija Nesic, John J Krais, Yifan Wang, et al.
Pageof 27